Symbols / EQ $2.00 +14.29% Equillium, Inc.

Healthcare • Biotechnology • United States • NCM
EQ Chart
About

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma. It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas. The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 126.45M
Enterprise Value 96.90M Income -22.40M Sales —
Book/sh 0.47 Cash/sh 0.48 Dividend Yield —
Payout 0.00% Employees — IPO —
P/E — Forward P/E -9.68 PEG —
P/S — P/B 4.30 P/C —
EV/EBITDA -4.12 EV/Sales — Quick Ratio 10.36
Current Ratio 10.58 Debt/Eq 2.51 LT Debt/Eq —
EPS (ttm) -0.39 EPS next Y -0.21 EPS Growth —
Revenue Growth — Earnings 2026-03-25 16:00 ROA -51.39%
ROE -94.00% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 63.23M
Shs Float 31.50M Short Float 4.19% Short Ratio 3.57
Short Interest — 52W High 2.70 52W Low 0.27
Beta 1.83 Avg Volume 545.42K Volume 344.31K
Target Price $5.50 Recom Strong_buy Prev Close $1.75
Price $2.00 Change 14.29%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.50
Mean price target
2. Current target
$2.11
Latest analyst target
3. DCF / Fair value
$-4.08
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.11
Low
$1.00
High
$12.00
Mean
$5.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-13 init Roth Capital — → Buy $12
2025-03-28 down Leerink Partners Outperform → Market Perform $1
2024-11-01 down Jones Trading Buy → Hold —
2024-08-19 reit HC Wainwright & Co. Buy → Buy $5
2024-06-05 reit HC Wainwright & Co. Buy → Buy $5
2024-05-17 reit HC Wainwright & Co. Buy → Buy $5
2024-04-02 main HC Wainwright & Co. Buy → Buy $5
2023-12-26 main HC Wainwright & Co. Buy → Buy $4
2023-11-13 main HC Wainwright & Co. Buy → Buy $5
2023-08-14 reit Cantor Fitzgerald Overweight → Overweight $3
2023-08-14 reit HC Wainwright & Co. Buy → Buy $6
2023-05-15 reit HC Wainwright & Co. Buy → Buy $6
2023-05-01 main HC Wainwright & Co. — → Buy $6
2023-03-24 main Stifel — → Buy $7
2023-02-08 main SVB Leerink — → Outperform $7
2022-09-27 main HC Wainwright & Co. — → Buy $20
2022-09-08 main SVB Leerink — → Outperform $12
2022-03-24 main HC Wainwright & Co. — → Buy $15
2022-01-05 main SVB Leerink — → Outperform $14
2021-09-15 init Cantor Fitzgerald — → Overweight $14
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-13 ZEDELMAYER CHRISTINE Chief Operating Officer — 120,312 $2.50 $300,816
2026-03-13 ZEDELMAYER CHRISTINE Chief Operating Officer — 120,312 $0.78 $94,445
2026-03-09 ZEDELMAYER CHRISTINE Chief Operating Officer — 181,219 $2.00 $362,438
2026-03-09 ZEDELMAYER CHRISTINE Chief Operating Officer — 152,361 $0.78 $119,603
2026-02-19 ZEDELMAYER CHRISTINE Chief Operating Officer — 185,937 $1.74 $328,104
2026-02-19 ZEDELMAYER CHRISTINE Chief Operating Officer — 185,937 $1.74 $328,104
2026-02-19 ZEDELMAYER CHRISTINE Chief Operating Officer — 185,937 $0.73 $141,750
2026-02-19 ZEDELMAYER CHRISTINE Chief Operating Officer — 185,937 $0.73 $141,750
2026-01-08 TOM PENNY Officer — 6,533 $1.29 $8,428
2025-12-23 ZEDELMAYER CHRISTINE Chief Operating Officer — 100,000 $1.50 $150,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
-100.00%
41.09
+13.89%
36.08
+128.97%
15.76
Operating Revenue
0.00
-100.00%
41.09
+13.89%
36.08
+128.97%
15.76
Operating Expense
23.63
-52.12%
49.36
-2.45%
50.61
-7.63%
54.79
Research And Development
12.84
-65.69%
37.43
+1.05%
37.04
-1.35%
37.55
Selling General And Administration
10.79
-9.59%
11.94
-12.02%
13.57
-21.30%
17.24
General And Administrative Expense
10.79
-9.59%
11.94
-12.02%
13.57
-21.30%
17.24
Other Gand A
10.79
-9.59%
11.94
-12.02%
13.57
-21.30%
17.24
Total Expenses
23.63
-52.12%
49.36
-2.45%
50.61
-7.63%
54.79
Operating Income
-23.63
-185.81%
-8.27
+43.06%
-14.52
+62.79%
-39.03
Total Operating Income As Reported
-23.63
-185.81%
-8.27
+43.06%
-14.52
+76.61%
-62.08
EBITDA
-23.52
-189.20%
-8.13
+33.00%
-12.14
+80.19%
-61.26
Normalized EBITDA
-23.52
-189.20%
-8.13
+33.00%
-12.14
+68.23%
-38.21
Reconciled Depreciation
0.12
-15.33%
0.14
+8.73%
0.13
+6.78%
0.12
EBIT
-23.63
-185.81%
-8.27
+32.58%
-12.26
+80.02%
-61.38
Total Unusual Items
—
—
0.00
+100.00%
-23.05
Total Unusual Items Excluding Goodwill
—
—
0.00
+100.00%
-23.05
Special Income Charges
—
—
0.00
+100.00%
-23.05
Other Special Charges
—
—
—
23.05
Net Income
-22.40
-177.65%
-8.07
+39.51%
-13.34
+78.64%
-62.43
Pretax Income
-22.40
-190.66%
-7.71
+39.58%
-12.76
+79.57%
-62.43
Net Non Operating Interest Income Expense
0.83
-39.68%
1.38
-25.07%
1.84
+391.15%
-0.63
Interest Expense Non Operating
—
0.00
-100.00%
0.49
-53.37%
1.05
Net Interest Income
0.83
-39.68%
1.38
-25.07%
1.84
+391.15%
-0.63
Interest Expense
—
0.00
-100.00%
0.49
-53.37%
1.05
Interest Income Non Operating
0.83
-39.68%
1.38
-40.83%
2.33
+455.71%
0.42
Interest Income
0.83
-39.68%
1.38
-40.83%
2.33
+455.71%
0.42
Other Income Expense
0.40
+149.27%
-0.82
-976.32%
-0.08
+99.67%
-22.77
Other Non Operating Income Expenses
0.40
+149.27%
-0.82
-976.32%
-0.08
-127.05%
0.28
Tax Provision
0.00
-100.00%
0.36
-37.76%
0.58
0.00
Tax Rate For Calcs
0.00
-100.00%
0.00
+0.00%
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-22.40
-177.65%
-8.07
+39.51%
-13.34
+78.64%
-62.43
Net Income From Continuing Operation Net Minority Interest
-22.40
-177.65%
-8.07
+39.51%
-13.34
+78.64%
-62.43
Net Income From Continuing And Discontinued Operation
-22.40
-177.65%
-8.07
+39.51%
-13.34
+78.64%
-62.43
Net Income Continuous Operations
-22.40
-177.65%
-8.07
+39.51%
-13.34
+78.64%
-62.43
Normalized Income
-22.40
-177.65%
-8.07
+39.51%
-13.34
+66.14%
-39.38
Net Income Common Stockholders
-22.40
-177.65%
-8.07
+39.51%
-13.34
+78.64%
-62.43
Diluted EPS
-0.39
-69.57%
-0.23
+39.47%
-0.38
+79.46%
-1.85
Basic EPS
-0.39
-69.57%
-0.23
+39.47%
-0.38
+79.46%
-1.85
Basic Average Shares
57.30
+62.07%
35.36
+1.82%
34.73
+2.96%
33.73
Diluted Average Shares
57.30
+62.07%
35.36
+1.82%
34.73
+2.96%
33.73
Diluted NI Availto Com Stockholders
-22.40
-177.65%
-8.07
+39.51%
-13.34
+78.64%
-62.43
Line Item Trend 2023-12-31
Total Assets
50.53
Current Assets
49.35
Cash Cash Equivalents And Short Term Investments
40.87
Cash And Cash Equivalents
23.22
Other Short Term Investments
17.65
Receivables
6.29
Accounts Receivable
3.73
Other Receivables
0.50
Taxes Receivable
2.05
Prepaid Assets
1.96
Other Current Assets
0.23
Total Non Current Assets
1.18
Net PPE
1.11
Gross PPE
1.48
Accumulated Depreciation
-0.36
Properties
0.00
Machinery Furniture Equipment
0.66
Other Properties
0.80
Leases
0.02
Other Non Current Assets
0.07
Total Liabilities Net Minority Interest
27.96
Current Liabilities
27.57
Payables And Accrued Expenses
11.40
Payables
4.71
Accounts Payable
4.71
Current Accrued Expenses
6.70
Total Tax Payable
0.00
Income Tax Payable
0.00
Current Debt And Capital Lease Obligation
0.44
Current Debt
—
Other Current Borrowings
—
Current Capital Lease Obligation
0.44
Current Deferred Liabilities
15.73
Current Deferred Revenue
15.73
Total Non Current Liabilities Net Minority Interest
0.38
Long Term Debt And Capital Lease Obligation
0.38
Long Term Debt
—
Long Term Capital Lease Obligation
0.38
Non Current Deferred Liabilities
0.00
Non Current Deferred Revenue
0.00
Stockholders Equity
22.57
Common Stock Equity
22.57
Capital Stock
0.00
Common Stock
0.00
Share Issued
35.25
Ordinary Shares Number
35.25
Treasury Shares Number
0.00
Additional Paid In Capital
208.17
Retained Earnings
-185.74
Gains Losses Not Affecting Retained Earnings
0.14
Other Equity Adjustments
0.14
Total Equity Gross Minority Interest
22.57
Total Capitalization
22.57
Working Capital
21.78
Invested Capital
22.57
Total Debt
0.82
Capital Lease Obligations
0.82
Net Tangible Assets
22.57
Tangible Book Value
22.57
Interest Payable
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-22.75
-19.55%
-19.03
+12.66%
-21.78
-149.43%
-8.73
Cash Flow From Continuing Operating Activities
-22.75
-19.55%
-19.03
+12.66%
-21.78
-149.43%
-8.73
Net Income From Continuing Operations
-22.40
-177.65%
-8.07
+39.51%
-13.34
+78.64%
-62.43
Depreciation Amortization Depletion
0.12
-15.33%
0.14
+8.73%
0.13
+6.78%
0.12
Depreciation
0.12
-15.33%
0.14
+8.73%
0.13
+6.78%
0.12
Depreciation And Amortization
0.12
-15.33%
0.14
+8.73%
0.13
+6.78%
0.12
Other Non Cash Items
—
-15.73
-71.53%
-9.17
-118.97%
48.33
Stock Based Compensation
2.32
-38.08%
3.75
-6.18%
4.00
-17.43%
4.84
Operating Gains Losses
-0.46
-157.30%
0.79
+1268.97%
0.06
-77.69%
0.26
Net Foreign Currency Exchange Gain Loss
-0.47
-159.70%
0.79
+1268.97%
0.06
-77.69%
0.26
Gain Loss On Sale Of PPE
0.02
0.00
—
—
Change In Working Capital
-2.32
-375.18%
0.84
+133.07%
-2.55
-13500.00%
0.02
Change In Receivables
0.00
-100.00%
3.73
+516.39%
-0.90
+68.39%
-2.84
Changes In Account Receivables
0.00
-100.00%
3.73
+516.39%
-0.90
+68.39%
-2.84
Change In Prepaid Assets
1.26
-44.48%
2.27
+226.04%
-1.80
-1042.41%
-0.16
Change In Payables And Accrued Expense
-3.62
+29.79%
-5.16
-3152.66%
0.17
-94.25%
2.94
Change In Accrued Expense
-1.69
+46.74%
-3.16
-471.12%
-0.55
-228.24%
0.43
Change In Payable
-1.94
+2.91%
-2.00
-375.93%
0.72
-71.17%
2.51
Change In Account Payable
-1.94
+2.91%
-2.00
-375.93%
0.72
-71.17%
2.51
Change In Other Working Capital
0.04
+566.67%
-0.01
+30.77%
-0.01
-117.33%
0.07
Change In Other Current Assets
—
—
—
—
Change In Other Current Liabilities
—
—
—
—
Investing Cash Flow
4.46
-67.68%
13.81
+390.09%
-4.76
-125.49%
18.68
Cash Flow From Continuing Investing Activities
4.46
-67.68%
13.81
+390.09%
-4.76
-125.49%
18.68
Net PPE Purchase And Sale
-0.04
+57.65%
-0.09
-70.00%
-0.05
+82.08%
-0.28
Purchase Of PPE
-0.05
+43.53%
-0.09
-70.00%
-0.05
+82.08%
-0.28
Sale Of PPE
0.01
0.00
—
—
Capital Expenditure
-0.05
+43.53%
-0.09
-70.00%
-0.05
+82.08%
-0.28
Net Investment Purchase And Sale
4.50
-67.62%
13.90
+394.97%
-4.71
-125.80%
18.26
Purchase Of Investment
0.00
+100.00%
-17.60
+67.83%
-54.71
-265.67%
-14.96
Sale Of Investment
4.50
-85.71%
31.50
-37.00%
50.00
+50.49%
33.23
Net Business Purchase And Sale
—
—
0.00
-100.00%
0.70
Financing Cash Flow
30.43
+18453.05%
0.16
+101.78%
-9.23
-659.51%
-1.22
Cash Flow From Continuing Financing Activities
30.43
+18453.05%
0.16
+101.78%
-9.23
-659.51%
-1.22
Net Issuance Payments Of Debt
—
0.00
+100.00%
-9.13
-539.12%
-1.43
Repayment Of Debt
—
0.00
+100.00%
-9.13
-539.12%
-1.43
Long Term Debt Payments
—
0.00
+100.00%
-9.13
-539.12%
-1.43
Net Long Term Debt Issuance
—
0.00
+100.00%
-9.13
-539.12%
-1.43
Net Common Stock Issuance
0.68
0.00
+100.00%
-0.26
0.00
Common Stock Payments
—
0.00
+100.00%
-0.26
0.00
Repurchase Of Capital Stock
—
0.00
+100.00%
-0.26
0.00
Proceeds From Stock Option Exercised
29.75
+18037.20%
0.16
-0.61%
0.17
-22.90%
0.21
Changes In Cash
12.14
+340.59%
-5.05
+85.89%
-35.77
-509.49%
8.74
Effect Of Exchange Rate Changes
0.05
+156.63%
-0.08
+29.66%
-0.12
-2460.00%
0.01
Beginning Cash Position
18.09
-22.10%
23.22
-60.72%
59.11
+17.35%
50.37
End Cash Position
30.28
+67.41%
18.09
-22.10%
23.22
-60.72%
59.11
Free Cash Flow
-22.79
-19.27%
-19.11
+12.47%
-21.83
-142.27%
-9.01
Interest Paid Supplemental Data
—
0.00
-100.00%
0.95
+11.69%
0.85
Income Tax Paid Supplemental Data
—
0.00
-100.00%
0.58
0.00
Amortization Of Securities
-0.01
+98.14%
-0.75
+17.51%
-0.91
-819.69%
0.13
Common Stock Issuance
0.68
0.00
—
0.00
Issuance Of Capital Stock
0.68
0.00
—
0.00
Sale Of Business
—
—
0.00
-100.00%
0.70
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category